Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by B Group Inc.

B Group Inc. reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 135,000 shares of the biopharmaceutical company’s stock after selling 42,600 shares during the period. Ultragenyx Pharmaceutical makes up approximately 3.1% of B Group Inc.’s investment portfolio, making the stock its 7th biggest position. B Group Inc. owned about 0.14% of Ultragenyx Pharmaceutical worth $4,061,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Assetmark Inc. lifted its position in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the period. Huntington National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $55,000. Smartleaf Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Covestor Ltd raised its position in Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $21.34 on Friday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -3.65 and a beta of 0.16. The stock has a fifty day moving average of $23.01 and a 200 day moving average of $28.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.39) EPS. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the transaction, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares in the company, valued at $15,025,063.20. This trade represents a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 104,958 shares of company stock valued at $2,394,858 over the last three months. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Guggenheim reduced their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a report on Monday, January 5th. Bank of America dropped their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. HC Wainwright reduced their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Robert W. Baird decreased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.76.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.